WANY
REGN icon

Wealthspire Advisors (New York)’s Regeneron Pharmaceuticals REGN Stock Holding History

Wealthspire Advisors (New York)’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.73M Buy
8,706
+5,463
+168% +$4.18M 0.05% 141
2025
Q4 		$2.5M Buy
3,243
+259
+9% +$176K 0.02% 264
2025
Q3 		$1.68M Sell
2,984
-3,153
-51% -$1.78M 0.01% 298
2025
Q2 		$3.22M Sell
6,137
-3,213
-34% -$1.79M 0.02% 211
2025
Q1 		$5.93M Buy
9,350
+3,731
+66% +$2.57M 0.04% 151
2024
Q4 		$4M Sell
5,619
-2,493
-31% -$2.09M 0.04% 163
2024
Q3 		$8.53M Buy
8,112
+7,643
+1,630% +$8.51M 0.09% 116
2024
Q2 		$493K Sell
469
-15
-3% -$14.5K 0.01% 435
2024
Q1 		$466K Sell
484
-54
-10% -$51.3K 0.01% 437
2023
Q4 		$473K Buy
538
+80
+17% +$65.9K 0.01% 427
2023
Q3 		$377K Buy
458
+16
+4% +$12.6K 0.01% 443
2023
Q2 		$318K Buy
442
+194
+78% +$150K 0.01% 452
2023
Q1 		$204K Sell
248
-39
-14% -$29.4K ﹤0.01% 503
2022
Q4 		$207K Buy
+287
New +$212K ﹤0.01% 534
2021
Q2 		– Sell
-718
Closed -$340K – 596
2021
Q1 		$340K Sell
718
-2,767
-79% -$1.35M 0.01% 516
2020
Q4 		$1.68M Buy
3,485
+618
+22% +$334K 0.05% 151
2020
Q3 		$1.6M Buy
2,867
+457
+19% +$277K 0.1% 100
2020
Q2 		$1.5M Buy
2,410
+310
+15% +$176K 0.1% 83
2020
Q1 		$1.02M Buy
2,100
+1,182
+129% +$488K 0.04% 195
2019
Q4 		$345K Sell
918
-27
-3% -$9.08K 0.03% 133
2019
Q3 		$262K Buy
+945
New +$280K 0.02% 132
2019
Q1 		– Sell
-182
Closed -$68K – 632
2018
Q4 		$68K Buy
+182
New +$66.6K 0.01% 152

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Wealthspire Advisors (New York)'s REGN Position: Q1 2026 in Review

Wealthspire Advisors (New York) increased its Regeneron Pharmaceuticals (REGN) stake by 168% in Q1 2026, buying an estimated $4.18M and bringing the position to 8,706 shares worth $6.73M. The position accounts for 0.05% of the portfolio, ranked #141.

Wealthspire Advisors (New York) first reported a position in REGN in Q4 2018 and has held it in 22 quarters since. The position peaked at $8.53M in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Wealthspire Advisors (New York) held 8,706 shares of Regeneron Pharmaceuticals worth $6.73M as of Q1 2026.
  • Wealthspire Advisors (New York) bought 5,463 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $4.18M.
  • Regeneron Pharmaceuticals made up 0.05% of Wealthspire Advisors (New York)'s portfolio in Q1 2026, its #141 holding.
  • Wealthspire Advisors (New York) first reported a position in Regeneron Pharmaceuticals in Q4 2018 and has held it in 22 quarters since.
  • Wealthspire Advisors (New York)'s Regeneron Pharmaceuticals position peaked at $8.53M in Q3 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q1 2026, filed 1 May 2026.